Dr. Floyd Bloom is professor emeritus in the Molecular and Integrative Neuroscience Department at The Scripps Research Institute (TSRI).
Dr. Bloom was previously founding CEO and board chairman of Neurome, Inc., chairman of the Department of Neuropharmacology at TSRI, director of Behavioral Neurobiology at the Salk Institute and chief of the laboratory of Neuropharmacology at the National Institute of Mental Health (NIMH).
In addition to RiverVest, Dr. Bloom has served on the scientific advisory boards of Merck, Inc. GlaxoSmithKline, Advancis Pharmaceutical Group (Middlebrook Pharmaceuticals), Saegis Pharmaceuticals, Inc., Elan Pharmaceuticals and Prothena, Inc. Dr. Bloom is a founder and director of Alkermes Corporation and director of AgeneBio, Inc.
A member of the National Academy of Sciences and the Institute of Medicine, Dr. Bloom has received numerous awards, including the Pasarow Award in Neuropsychiatry and the Hermann van Helmholtz Award, the Sarnat Award for Mental Health Research, as well as a number of honorary degrees from major universities.
Dr. Bloom is past editor-in-chief of Science magazine and has authored or co-authored more than 25 books and monographs and more than 400 original research articles.
Dr. Bloom received his M.D. from Washington University School of Medicine and his A.B. from Southern Methodist University. He also completed a U.S. Public Health Service Commissioned Corps special post-doctoral fellowship at Yale University.